Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals is a biotechnology company focused on bringing the designed deoxyribonucleic acid (DNA) medicines to treat, cure, and protect people from diseases associated with human papillomavirus, cancer, and infectious diseases. The company's DNA medicine pipeline is comprised of three types of product candidates, DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies. The company's DNA medicine candidates are made using its proprietary SynCon? technology that creates plasmids, which are circular strands of DNA that can produce antigens inside a cell to help the person's immune system recognize and destroy cancerous or infected cells.
  • TickerINO
  • ISINUS45773H2013
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
INO Inovio Pharmace... (Health Care)

Thanks to a better fundamental star rating, INOVIO PHARMACEUTICALS see...

The independent financial analyst theScreener just awarded an improved star rating to INOVIO PHARMACEUTICALS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 3 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date January 29, 2021, the closing price was USD 12.75 and its expected value was estimated at USD 10.10.

INO Inovio Pharmace... (Health Care)

Thanks to a better fundamental star rating, INOVIO PHARMACEUTICALS see...

The independent financial analyst theScreener just awarded an improved star rating to INOVIO PHARMACEUTICALS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 3 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date January 29, 2021, the closing price was USD 12.75 and its expected value was estimated at USD 10.10.

INO Inovio Pharmace... (Health Care)

Thanks to a better fundamental star rating, INOVIO PHARMACEUTICALS see...

The independent financial analyst theScreener just awarded an improved star rating to INOVIO PHARMACEUTICALS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 3 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date January 29, 2021, the closing price was USD 12.75 and its expected value was estimated at USD 10.10.

INO Inovio Pharmace... (Health Care)

Thanks to a better fundamental star rating, INOVIO PHARMACEUTICALS see...

The independent financial analyst theScreener just awarded an improved star rating to INOVIO PHARMACEUTICALS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 3 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date January 29, 2021, the closing price was USD 12.75 and its expected value was estimated at USD 10.10.

INO Inovio Pharmace... (Health Care)

Thanks to a better fundamental star rating, INOVIO PHARMACEUTICALS see...

The independent financial analyst theScreener just awarded an improved star rating to INOVIO PHARMACEUTICALS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 3 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date January 29, 2021, the closing price was USD 12.75 and its expected value was estimated at USD 10.10.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch